PHILADELPHIA - Johnson & Johnson (NYSE: JNJ) today unveiled results from the Phase 3 GRAVITI study, highlighting the effectiveness of TREMFYA® (guselkumab) in treating Crohn's disease (CD). The study found that a greater number of patients achieved clinical and endoscopic remission after 48 weeks of treatment with subcutaneous TREMFYA® compared to those receiving a placebo.
The GRAVITI study assessed the efficacy of TREMFYA®, an IL-23 inhibitor, as a subcutaneous induction and maintenance therapy for adults with moderately to severely active CD. Over half of the patients treated with TREMFYA® reached clinical remission at week 12, with significant improvements observed as early as week 4. By week 48, the rates of clinical remission were more than three times higher for patients on TREMFYA® maintenance doses compared to the placebo group.
Dr. Remo Panaccione, a study investigator, noted the rapid and robust response with subcutaneous guselkumab, potentially offering a new treatment option for CD. The study's one-year results suggest that this treatment approach could help patients manage symptoms and achieve meaningful endoscopic improvements.
Pending FDA approval, TREMFYA® could become the first IL-23 treatment to offer both subcutaneous and intravenous induction regimens for CD patients. The drug has already been approved by the FDA for the treatment of adults with moderately to severely active ulcerative colitis (UC) in September 2024, and an application for CD treatment is currently under review.
The safety profile of TREMFYA® was reinforced by the study's findings. Johnson & Johnson emphasizes that the convenience of self-administration from the start of treatment aligns with their commitment to delivering innovative therapeutic solutions to people with CD.
This report is based on a press release statement from Johnson & Johnson.
In other recent news, Johnson & Johnson reported strong third-quarter results with operational sales growth of 6.3%, reaching $22.5 billion. The company raised its full-year guidance for the third consecutive quarter, despite facing challenges in certain markets. Analysts from RBC Capital Markets and Stifel Financial (NYSE:SF) have raised their price targets for Johnson & Johnson following these strong results. However, the company has also been ordered to pay $15 million in a talc cancer case, a decision they plan to appeal. These are some of the recent developments for Johnson & Johnson. Despite facing legal challenges, the company's financial performance and the analysts' positive outlook underscore the firm's resilience and potential for continued growth.
InvestingPro Insights
Johnson & Johnson's latest clinical trial results for TREMFYA® align with the company's strong position in the pharmaceutical industry. According to InvestingPro data, J&J boasts a substantial market capitalization of $387.34 billion, underscoring its significance in the healthcare sector. The company's revenue growth of 4.77% over the last twelve months and a robust gross profit margin of 69.16% reflect its ability to generate value from its product portfolio, including potential new treatments like TREMFYA® for Crohn's disease.
InvestingPro Tips highlight J&J's financial stability and consistent performance. The company has raised its dividend for 54 consecutive years, demonstrating a long-term commitment to shareholder returns. This is particularly relevant given the potential for new revenue streams from expanded indications for drugs like TREMFYA®. Additionally, J&J operates with a moderate level of debt, which provides financial flexibility to invest in research and development for innovative treatments.
The company's strong market position is further evidenced by its prominence in the pharmaceuticals industry, as noted in another InvestingPro Tip. This aligns with J&J's ongoing efforts to expand its treatment offerings, as seen with the GRAVITI study results.
For investors interested in a deeper analysis, InvestingPro offers 11 additional tips for Johnson & Johnson, providing a comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.